A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects

Sponsor
Shandong Suncadia Medicine Co., Ltd.
Study ID
NCT07557407
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Chronic Kidney Diseases

Eligibility Criteria

Sex
MALE
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • [14C]HRS-1780 — DRUG
    \[14C\]HRS-1780, oral.

Study Details

The study aims to evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \[14C\]HRS-1780 following an oral single dose in healthy adult male participants.

Key Dates

First listed
Apr 29, 2026
Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
6 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: [14C]HRS-1780 Group
    Oral, single dose.

Primary Outcome Measure

Total radioactivity ratio of whole blood/plasma. [ Time Frame: 0 to anticipated 11 days. ]

Central Contacts

Related Studies